Our data supports that both AML containing RUNX1-ETO9a and MLL-AF9 fusion proteins are dependent on PHF6 for their function, and that PHF6 may be a potential LSC-directed therapeutic target for AML. Here, MLLT3 is linked to acute myeloid leukemia.